Skip to content

Filter by:

Keyword

Dragon AC, Thoelke S, Mausberg P, Zimmermann K, Blasczyk R, Hudecek M, Abken H, Schambach A, Maecker-Kolhoff B, Eiz-Vesper B. LMP2A-Targeting CAR-T Cells Equipped With Inducible IL-18 to Address EBV-Associated Malignancies. HLA. 2025 Oct. 106:e70439. doi:10.1111/tan.70439. PMID: 41116979

Buckley S, Miao Y, Idris M, Lee P-W, Scheller L, Riek R, Maerkl SJ, Abriata LA, Correia BE. 2025

De novo design of phosphorylation-induced protein switches for synthetic signaling in cells doi:10.1101/2025.09.10.675034.

Thomas S, Wermke M, Vucinic V, Wagner-Drouet E, Mackensen A, Zeiser R, Bug G, Schmitt M, Herr W, Prinz PU, Burdek M, Raffegerst S, Tafuri A, Geiger C, Crame K, Goedkoop R, Pinkernell K, Schendel DJ. First-in-Human Study of MDG1011, a TCR-T Therapy Directed Against HLA-A*02:01-Restricted PRAME Antigen for High-Risk Myeloid and Lymphoid Neoplasms. Cancers (Basel). 2025 Sep 11. 17doi:10.3390/cancers17182968. PMID: 41008812

Piekarska A, Abouqateb M, Boreland W, Peczynski C, Zaucha JM, Kroger N, Zeiser R, Ciceri F, Schroeder T, Luft T, Passweg J, Kunadt D, Stelljes M, Blau IW, Platzbecker U, Yakoub-Agha I, Blaise D, Raiola AM, Tischer J, Wagner-Drouet EM, Winkler J, Schmid C, Wulf G, Edinger M, Maertens J et al. Improved GVHD-free relapse-free survival when rATG/ATLG is used in allo-HCT from matched sibling donors – an EBMT registry study by the Transplant Complications Working Party. Bone Marrow Transplant. 2025 Sep 11. doi:10.1038/s41409-025-02692-1. PMID: 40931084

Nozari Z, Huttl P, Simeth J, Schon M, Hutchinson JA, Spang R. Harp: data harmonization for computational tissue deconvolution across diverse transcriptomics platforms. Bioinformatics. 2025 Sep 1. 41doi:10.1093/bioinformatics/btaf455. PMID: 40857392

Hansmann H, Henkel C, Fante MA, Harrer DC, Heidemanns S, Oellerich M, Beck J, Schutz E, Biswenger V, Perl M, Zartner B, Edinger M, Wolff D, Hoffmann P, Herr W, Banas B, Zecher D, Hansmann L. Sustained allogeneic kidney graft operational tolerance despite discontinued conventional immunosuppression after CD19-CAR-T cell therapy for relapsed/refractory posttransplant lymphoproliferative disorder. Am J Transplant. 2025 Sep 17. doi:10.1016/j.ajt.2025.09.009. PMID: 40972901

Teubner JP, Tumen D, Kandulski A, Heumann P, Mester P, Aschenbrenner E, Pollinger K, Gunckel M, Volz B, Hein T, Beltzig PL, Tengler L, Voll F, Kreutz M, Kunst C, Nicolay JP, Muller M, Gulow K. CRISPR-Cas9 screen reveals that inhibition of enhancer of zeste homolog 2 sensitizes malignant T cells to dimethyl-fumarate-induced cell death. FEBS J. 2025 Aug 1. doi:10.1111/febs.70208. PMID: 40748748

Perl M, Fante MA, Herfeld K, Scherer JN, Poeck H, Thiele Orberg E. Microbiota-derived metabolites: Key modulators of cancer immunotherapies. Med. 2025 Aug 8. 6:100773. doi:10.1016/j.medj.2025.100773. PMID: 40695291

Knoedler L, Herfeld K, Schaefer DA, Diatta F, Clune J, Evans B, Seu M, Kim BS, Alfertshofer M, Schaschinger T, Iske J, Knoedler S, Lellouch AG, Jeljeli M, Carturan A, Ruella M, Heiland M, Poeck H, Perl M, Pomahac B, Kauke-Navarro M. CAR-T cell therapy and reconstructive oncologic surgery in peripheral solid tumors-A narrative review. Cell Rep Med. 2025 Aug 19. 6:102240. doi:10.1016/j.xcrm.2025.102240. PMID: 40675157

Givi S, Lohnes BJ, Ebrahimi S, Riedel S, Khokhali S, Khan SA, Keller M, Wolfel C, Echchannaoui H, Bockamp E, Andre MC, Abken H, Theobald M, Hartwig UF. CRISPR/Cas9 TCR-Edited NKp30 CAR T Cells Exhibit Superior Anti-Tumor Immunity to B7H6-Expressing Leukemia and Melanoma. Int J Mol Sci. 2025 Aug 25. 26doi:10.3390/ijms26178235. PMID: 40943160